Novartis (Australia)

Recent papers from Novartis (Australia)

1. Prevalence of Lipoprotein(a) Testing in Patients With Atherosclerotic Cardiovascular Disease Within a Large Australian Cardiology NetworkHeart Lung and Circulation · 2026
2. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Australian HospitalsNeurology and Therapy · 2025
3. Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-OffPharmacoEconomics - Open · 2024
4. ASC4REAL: Efficacy and tolerability comparison between ASCEMBL study, a phase 3 randomized clinical trial (RCT), and consolidated real-world (RW) experience with asciminib (ASC) in patients with CML beyond two TKIs.Journal of Clinical Oncology · 2024
5. Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisonsTherapeutic Advances in Neurological Disorders · 2024
6. Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment ArrangementPharmacoEconomics · 2022
7. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE studyAustralasian Journal of Dermatology · 2022
8. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice (SUSTAIN study)Australasian Journal of Dermatology · 2022
9. Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL datasetClinical Rheumatology · 2021
10. Clinical Characteristics of People with Heart Failure in Australian General Practice: Results from a Retrospective Cohort StudyESC Heart Failure · 2021
11. Epidemiology of Heart Failure: Study of Heart Failure in the Australian Primary CarE Setting (SHAPE)ESC Heart Failure · 2020
12. Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS studyMultiple Sclerosis Journal - Experimental Translational and Clinical · 2020
13. The epidemiology of heart failure in the general Australian community - study of heart failure in the Australian primary carE setting (SHAPE): methodsBMC Public Health · 2020
14. 049 Real world evidence (RWE) on impact of age on long-term persistence to disease modifying therapies (DMTS) in relapsing-remitting multiple sclerosis (RRMS) in australiaJournal of Neurology Neurosurgery & Psychiatry · 2019
15. Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion‐dependent anemia: the TIMES studyHemaSphere · 2019
16. The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic settingBMC Cancer · 2019
17. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift studyLeukemia Research · 2018
18. Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 studyEuropean Journal of Cancer Care · 2017
19. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study)European Journal Of Haematology · 2016
20. Mapping the testicular interstitial fluid proteome from normal ratsPROTEOMICS · 2016